The British pharmaceutical company AstraZeneca has announced that it will invest 15 billion dollars (approximately 12.6 billion euros) in China by 2030 to expand drug production and research[1]. This is the company's largest investment in China to date[1]. China is AstraZeneca's second largest market after the United States[1]. The investment also includes the creation of a new global strategic research and development center in Beijing with an investment of 2.5 billion dollars, where the company plans to increase the number of employees to 1,700[3]. The company's first vaccine factory in China will also be built in Beijing in cooperation with partner BioKangtai[3]. The new Beijing center will be AstraZeneca's sixth research and development center in the world and the second in China, where it already operates a site in Shanghai[3]. The center will be equipped with a modern artificial intelligence and data processing laboratory to support early research and clinical development[3]. AstraZeneca has been operating in China for over thirty years[1].